Podcasts about aristea

In our latest episode of the Healthy Seas Podcast, we explored an innovative approach to education that's not just about learning—it's about living and interacting with the world around us. Our guest, Dr. Aristea Kyriakou, founder of the European Outdoor Education Hub, shares fascinating insights on how outdoor education can transform not only how students learn but also how they connect with their environment.Outdoor education is more than just taking lessons outside. It's a comprehensive methodology and philosophy that places students in natural settings, engaging them directly with their environment. Unlike traditional classroom-based instruction, which often relies on theoretical learning, outdoor education emphasizes experiential learning. This approach allows students to interact with their surroundings, engage multiple senses, and gain practical understanding through hands-on activities.Aristea's work with Healthy Seas in our Operation Ghost Farms exemplifies this methodology. By combining cleanups of abandoned fish farms with educational activities for kids, the program not only addresses immediate environmental issues but also fosters a deep, personal connection between students and their natural surroundings.Listen to the full episode to learn how outdoor education can revolutionize learning and inspire future environmental stewards.If you enjoyed this episode, please be sure to subscribe, rate and review it! This helps to boost its visibility. Healthy Seas is a marine conservation organization whose mission is to tackle the ghost fishing phenomenon and turn this waste into an opportunity for a more circular economy. They do this through clean-ups, prevention, education, and working with partners who recycle and repurpose this material. The podcast is hosted by Crystal DiMiceli.

POTERE AL POPOLO – S.VARIN – ARISTEA – M.MOLETTI – 28 – 02 – 2023

In this episode of the Biotech and Breweries Podcast, James Mackey, CEO of Aristea Therapeutics, a clinical-stage drug development company focused on immunology-focused therapeutics to treat autoimmune and inflammatory diseases. James shares the origin story of Aristea and his long professional history in life sciences. He also shares how fundraising allowed Aristea to extend its development, how Aristea is contributing to the life sciences industry in San Diego, and how the company is finding ways to positively impact the community. Quote:“What makes San Diego so special to me is the collaborative nature of everyone here. People are delighted you are here and they want you to succeed. They will do what they can to help you succeed even if you are a competitor because they see success as success for San Diego.” - James Mackey [22:22]Topics discussed:James' professional journey The origins of Aristea and RIST4721Fundraising and the life sciences financial market Life Science Cares San Diego and SD2Resources:Connect with James Mackey:LinkedinSUBSCRIBE: Subscribe to the podcast to make sure you never miss an episode.

Synopsis: This special episode features a panel discussion with three biotech leaders about drug development for rare diseases. James Mackay, Ph.D., is the Founder, President and CEO of Aristea Therapeutics, an immunology-focused clinical stage biotech that is focused on inflammatory diseases. Arthur T. Suckow, Ph.D., is the Co-Founder and CEO of DTx Pharma, which is focused on developing novel technology for delivery of RNA medicines. Eslie Dennis is the SVP and CMO of Kyowa Kirin North America, a Japan-based global specialty pharmaceutical company. Our guests discuss the patient journey for those living with rare diseases, the importance of driving awareness for this patient population, important points to consider when partnering with big pharma, clinical trial design for patients with rare diseases, and best practices for driving awareness and inclusion of people of color in rare disease trials. Biography: James Mackay, Ph.D., Founder, President and Chief Executive Officer, has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. Prior to founding Aristea, he was President and Chief Executive Officer of Ardea Biosciences, Inc., following the company's acquisition by AstraZeneca in 2012. James was instrumental to setting up an innovative model for Ardea Biosciences that retained the biotech's independence and accountability for the development of the gout franchise while also developing a synergistic and collaborative relationship with the parent company, AstraZeneca. Prior to Ardea, James held senior executive positions at AstraZeneca where he led the development and commercialization of drugs across a range of therapy areas. and managed significant global functional departments. James plays a pivotal role in the San Diego Ecosystem and currently sits on the Board and Executive Committee of CONNECT and sits on the Board of BIOCOM. He is a former Board member of the San Diego Economic Development Corporation (EDC). James holds a BS in Genetics and Ph.D. in Medical Genetics from Aberdeen University, Scotland. Dr. Arthur Suckow founded DTx Pharma in 2017. An innovative leader in drug discovery, he previously worked on the ophthalmology, diabetes, and NASH programs at Regulus Therapeutics, at the MedImmune arm of AstraZeneca, and in the Diabetes Drug Discovery program at Johnson & Johnson. Dr. Suckow received his BS from the University of Delaware and his PhD from University of California, San Diego. He has received numerous awards including a Beckman Fellowship, a NSF graduate research fellowship, and a BIOCOM catalyst award. Dr. Eslie Dennis joined Kyowa Kirin in May 2021 as SVP, Chief Medical Officer for Kyowa Kirin North America. Prior to joining this organization, she was Vice President and Head Global Medical Affairs at Ventana/Roche Tissue Diagnostics. She is a physician with 10 years experience in clinical practice (internal medicine and hematology/oncology) and research, and over 20 years international biopharma experience holding positions of increasing responsibility in pharmaceutical and diagnostic organizations at MSD, Novartis and Roche, including leadership of public-private consortia at the Critical Path Institute. Throughout her career, Dr. Dennis has championed innovative science and solutions to address unmet needs for patients and society, particularly addressing healthcare disparities. Dr. Dennis received her MBChB from the Godfrey Huggins School of Medicine in Harare, Zimbabwe, and was the recipient of the Winston Churchill, Margaret Low, and Prankard-Jones Scholarships, as well as the Guy Elliot Bursary. She is a Fellow of the College of Physicians of South Africa and received her internal medicine and hematology/oncology training at Groote Schuur Hospital in Cape Town, South Africa.

Quinta tappa di questo speciale viaggio che ci accompagnerà verso il Festival del Gioco torinese ToPlay alla sua quinta edizione: Beyond The Horizon! In questa puntata Aristea con Dario Leccacorvi ci presenta il progetto editoriale, in questa occasione approfondiamo l'argomento librogame che li vede molto attivi ma anche Rayn prende la sua parte, tra poco verrà distribuito il kickstarter del gioco di ruolo Esoteric Fantasy... avrete la possibilità di conoscere il loro mondo e di provare una delle loro avventure!!! il 3 e 4 settembre al parco della tesoriera.Buon ascolto e spero tanto di vedervi a Torino per fare una partita insieme. Link utili della puntata:Aristea: https://www.edizioniaristea.it/ToPlay: https://www.facebook.com/toplaytorinoAroundTheGame: https://linktr.ee/aroundthegameMusic from Uppbeat (free for Creators!):https://uppbeat.io/t/soundroll/good-thingLicense code: 9ADYJIP84PILLIQ3

James Mackay is the Founder, President, and CEO of Aristea Therapeutics, a San Diego-based company that is applying its insights on neutrophils to develop a treatment for a rare inflammatory skin condition known as palmoplantar pustulosis, PPP. Most of the people who get this disease are postmenopausal females, and 90%+ of the patients either are current cigarette smokers or have a history of cigarette smoking.  James explains, "So neutrophils are cells that are part of the immune system. They sit in the bone marrow, and then when there's either an infection or an inflammatory response in the body, the neutrophils are attracted out of the bone marrow to the site of infection or inflammation. In inflammatory diseases, what you often see is extremely large numbers of neutrophils accumulating at the site of the inflammation, which obviously causes some challenges for the patients." "And in our particular case, we have a drug, it's called RIST4721, which is a CXCR2 antagonist which actually blocks the neutrophils moving from the bone marrow to the site of inflammation. And we believe that this is potentially a way to treat a whole range of serious inflammatory diseases." "So there's definitely a direct link to cigarette smoking. There's not much basic research been done on PPP, so the exact reason for that is not clear, but we believe, based on some of the research, that it's due to the nicotine receptor in the sweat ducts on the palms of the hands and the soles of the feet. And the sweat ducts on the hands and the feet are different structures from those elsewhere in the body, which is why this disease probably just affects the palms of the hands and the soles of the feet." @AristeaTx #PPP #PalmoplantarPustulosis #RareDisease #Inflammation #Neutrophils #SanDiego aristeatx.com Listen to the podcast here

James Mackay is the Founder, President, and CEO of Aristea Therapeutics, a San Diego-based company that is applying its insights on neutrophils to develop a treatment for a rare inflammatory skin condition known as palmoplantar pustulosis, PPP. Most of the people who get this disease are postmenopausal females, and 90%+ of the patients either are current cigarette smokers or have a history of cigarette smoking.  James explains, "So neutrophils are cells that are part of the immune system. They sit in the bone marrow, and then when there's either an infection or an inflammatory response in the body, the neutrophils are attracted out of the bone marrow to the site of infection or inflammation. In inflammatory diseases, what you often see is extremely large numbers of neutrophils accumulating at the site of the inflammation, which obviously causes some challenges for the patients." "And in our particular case, we have a drug, it's called RIST4721, which is a CXCR2 antagonist which actually blocks the neutrophils moving from the bone marrow to the site of inflammation. And we believe that this is potentially a way to treat a whole range of serious inflammatory diseases." "So there's definitely a direct link to cigarette smoking. There's not much basic research been done on PPP, so the exact reason for that is not clear, but we believe, based on some of the research, that it's due to the nicotine receptor in the sweat ducts on the palms of the hands and the soles of the feet. And the sweat ducts on the hands and the feet are different structures from those elsewhere in the body, which is why this disease probably just affects the palms of the hands and the soles of the feet." @AristeaTx #PPP #PalmoplantarPustulosis #RareDisease #Inflammation #Neutrophils #SanDiego aristeatx.com Download the transcript here

James Mackay, PhD, Founder, President and Chief Executive Officer of Aristea Therapeutics, has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. James joins The Dudes to discuss his experience and how he is contributing to and benefiting from the biotech leadership community. 

This episode of BioTech IQ features James Mackay, PhD, Founder and CEO of Aristea Therapeutics. Aristea Therapeutics is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases. In particular, their lead asset is addressing palmoplantar pustulosis (PPP), a rare, chronic inflammatory skin condition with no approved therapy in the United States that affects about 100,000 people.Don't miss this episode as we discuss James' background and the strategy of Aristea's approach to their current asset.https://aristeatx.com/Check out out more episodes at https://thebiotechiqpodcast.com/

Aristea Therapeutics was spun out of AstraZeneca to develop medicines for rare, immunologic disorders. Its lead program in development is an experimental therapy for a rare skin condition that causes repeated outbreaks of painful pustules on the hands and feet and is being looked at for other neutrophil-mediated diseases. We spoke to James Mackay, president and CEO of Aristea, about the decision to form the company, its lead therapy in development, and its collaboration and development deal with Arena Pharmaceuticals that gives its partner an option to acquire it outright.

Why has Gout been an incredibly challenging condition for many individuals to treat? Even though treatments have been developed and used, Gout flares can remain, being an incredibly painful and diminishing quality of life. Listen up to learn: the predominant problem for patients with Gout the specific gene that should be tested for Why Gout tophi can cause issues Nihar Bhakta, the CMO of Aristea Therapeutics, speaks about treating Gout and giving patients lasting relief. Gout has long troubled patients, causing severe inflammatory reactions and limiting motion and quality of life. However, lowering uric acid is the primary treatment method and can remain challenging for some patients. If patients are mistreated over time, they can go on to develop kidney issues, which may even begin to turn chronic. Hopefully, with further development, Aristea and a handful of other companies can produce treatments to reduce uric acid while limiting possible adverse effects. Visit https://aristeatx.com to learn more. Episode also available on Apple Podcast: http://apple.co/30PvU9C

Con una campagna Kickstarter in dirittura d'arrivo ed una raccolta fondi di tutto rispetto sta per arrivare RAYN il gioco di ruolo di Aristea! Di cosa parla il gioco? Perché potrebbe fare al caso vostro? Deve entrare nella vostra collezione e sul vostro tavolo da gioco?Intervista con Dario Leccacorvi, AndreaTupac Mollica e Fabio Porfidia per scoprire tutto sul prodotto dalla sua genesi alla scrittura passando dal comparto grafico ed artistico!Taaaaaaaaaaaaaaaaaaaaac!

James Mackay, PhD, Founder, President and Chief Executive Officer, has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. Prior to founding Aristea, he was President and Chief Executive Officer of Ardea Biosciences, Inc., following the company's acquisition by AstraZeneca in 2012. James was instrumental to setting up an innovative model for Ardea Biosciences that retained the biotech's independence and accountability for the development of the gout franchise while also developing a synergistic and collaborative relationship with the parent company, AstraZeneca. Prior to Ardea, James held senior executive positions at AstraZeneca where he led the development and commercialization of drugs across a range of therapy areas. and managed significant global functional departments. James plays a pivotal role in the San Diego Ecosystem and currently sits on the Board and Executive Committee of CONNECT and sits on the Board of BIOCOM. He is a former Board member of the San Diego Economic Development Corporation (EDC). James holds a BS in Genetics and PhD in Medical Genetics from Aberdeen University, Scotland.

In compagnia di Dario Leccacorvi, diamo uno sguardo al mondo di RAYN, dai librigioco usciti fino ad ora, fino al gioco di ruolo che debutterà a Febbraio su Kickstarter! Quale sentiero sceglierete: Luce, Tenebra o Abisso? ----more---- Scaletta: [00:00:47] Meet Dario Leccacorvi [00:03:49] Presentazione Rayn [00:16:32] Cosa sono gli Apprendistati [00:19:40] Luce, tenebra e Abisso [00:23:45] La crescita del personaggio lungo i sentieri del Trimundio [00:32:15] Lo stile grafico di Rayn [00:39:30] La lore di Rayn e i librigame [00:42:25] Dal Libro game al GDR - I due sistemi [00:45:05] Il sistema di gioco [00:51:30] Anticipazioni sul Kickstarter e il concorso "diventa un autore" [00:55:35] Fatti una domanda e datti una risposta [00:57:20] I canali di Aristea [01:00:50] Appuntamenti, suggerimenti e saluti   Ne potete parlare sul Discord di The World Anvil: https://bit.ly/discord-twa Qui potete trovare il quickstart di Rayn: https://www.edizioniaristea.it/page2.html E qui potete raggiungere la community: https://www.facebook.com/groups/377755837170054 Potete scriverci a rollagain@theworldanvil.com Ci trovate anche su iTunes QUI e YouTube QUI. Su Twitter: http://www.twitter.com/rollagaincast e http://www.twitter.com/theworldanvil Link allo store di The World Anvil   Hanno partecipato a questo episodio: Giorgio Catenacci Riccardo Vacirca Fabrizio Infusino Valerio Votadoro Dario Leccacorvi

ARISTEA: LIBRI GAME E MOLTO DI PIUSu Casa Kilamdil intervistiamo Dario Leccacorvi di @edizioniaristea, per scoprire la storia di questa realtà editoriale che ha saputo affermarsi con potenza nel mondo dei libri game e curioseremo le novità in arrivo e quelle appena uscite sul mercato!

This episode featuring James Mackay, President & CEO of Aristea Therapeutics. James provides insights on his experience with setting up a biotech and challenges associated, industry climate on spin off opportunities, Aristea's pipeline, collaborations and US PRMA reforms. Presenter: Aparna Krishnan Contributors: James Mackay, President & CEO of Aristea Therapeutics Producer: Operations team About Aristea Therapeutics, a San Diego-based clinical-stage immunology-focused drug development company developing novel therapies for serious, rare inflammatory diseases.

Aristea is developing drugs for inflammatory diseases, starting with palmoplantar pustulosis. James shares his journey from small town Scotland to big pharma and San Diego

Questa terza e ultima puntata della trilogia dedicata a ToPlay ci vede in compagnia di Dario Leccacorvi prima volta davanti al microfono della piccola mongolfiera colorata ma ci racconta un gioco molto molto curioso e che io andrò sicuramente a spulciare. Sarà possibile incontrarlo al ToPlay a Torino 11 e 12 Settembre al parco della Tesoriera e provare così il suo Rayn al microfono Dario LeccacorviQui puoi trovare il progetto: https://www.facebook.com/AristeaEditoreQui il quickstart di Rayn: https://www.edizioniaristea.it/Seguite la Mongolfiera di Around The Game:www.aroundthegame.itCanale Telegram: https://t.me/aroundthegame Facebook: https://www.facebook.com/AroundTheGame.podcast/ Instagram: https://www.instagram.com/aroundthegame/Questo progetto è seduto sul Divano Cosmicowww.divanocosmico.it

Siamo arrivati alla terza puntata con Brandy! Continua il viaggio nel mondo fantasy un po' scalcinato e fuori di testa di Infinity Mundi. Brandy a tutta birra, stiamo arrivando!

This week Patrick talks to Nihar Bhakta as part of our series of ‘Precision Pioneers'. Dr Bhakta is the Chief Medical Officer at Aristea Therapeutics, a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases. Dr Bhakta specialises in precision medicine and in this episode they focus on his work developing precision medicines for both common and rare diseases. This is the second episode in a mini-series on ‘Precision Pioneers' - stay tuned for more episodes in this area and find previous episodes by searching for The Genetics Podcast on any podcast provider.

This week Patrick talks to Nihar Bhakta as part of our series of ‘Precision Pioneers’. Dr Bhakta is the Chief Medical Officer at Aristea Therapeutics, a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases. Dr Bhakta specialises in precision medicine and in this episode they focus on his work developing precision medicines for both common and rare diseases. This is the second episode in a mini-series on ‘Precision Pioneers’ - stay tuned for more episodes in this area and find previous episodes by searching for The Genetics Podcast on any podcast provider.

Dopo il successo della prima puntata, continuiamo il nostro viaggio nel mondo fantasy un po' scalcinato e di sicuro fuori dai classici schemi con Infinity Mundi. Brandy a tutta birra stiamo arrivando!

Dal cartaceo all'elettronico. cosa ne pensate? Possiamo parlare di Ebook game? Abbiamo provato con voi un librogame su app, fuori dai classici schemi con Infinity Mundi. Ambientazione Fantasy medievale dai tratti demenziali e comici. Il podcast è tratto da una intervista live tenuta sui canali social di Casa Kilamdil, potrebbero esserci pertanto dei riferimenti ad elementi visti non visionabili ovviamente ascoltando solo l'audio

Dr Aristea Fotopoulou, UKRI Innovation Fellow/AHRC Leadership Fellow and Postgraduate Research coordinator in the School of Media discusses her ART / DATA / HEALTH research project, which uses creative material for health and wellbeing. Dr Fotopoulou talks in depth about Shielding and 104 Days Later, which are both part of the online Brighton Fringe.

Join us for a friendly book club-style discussion of contemporary music. Check out Listening List 7 on our website to hear the pieces we talk about in this episode: https://www.newmusiclisteningclub.com/post/episode-7-listening-list-gunn-zajkowski-hsieh-twist Timings for piece discussions:6:05 Gunn38:11 Hsieh1:09:09 TwistJoin the conversation on Twitter (@ListeningNew), Facebook (@NewMusicListeningClub), on our website blog, or email us: newmusiclisteningclub@gmail.comRate and review this episode and subscribe! Our next episode will be coming out soon.

Gaetano Donizetti’s ‘mini opera’ Aristea follows the 19th-century fashion for composing celebratory scenic works with a large cast and full orchestra, in this case to honour Ferdinand I, King of the Two Sicilies. Librettist Giovanni Schmidt recycled Aristea from an earlier abandoned opera set in idyllic Greek surroundings. This tells the classical story of enforced separation of a father from his daughter, their subsequent confusions and final happy reunion. Donizetti’s early style was influenced by Rossini but is nevertheless independent and innovative, often hinting at his later operatic masterpieces. Classical Music Discoveries is sponsored by La Musica International Chamber Music Festival and Uber. @khedgecock #ClassicalMusicDiscoveries #KeepClassicalMusicAlive #LaMusicaFestival #CMDGrandOperaCompanyofVenice #CMDParisPhilharmonicinOrléans #CMDGermanOperaCompanyofBerlin #CMDGrandOperaCompanyofBarcelonaSpain #ClassicalMusicLivesOn #Uber Support us on Patreon https://www.patreon.com/user?u=4186107

Stabat Mater, a medieval hymn that was long used as the sequence for the Feast of the Seven Sorrows of the Blessed Virgin Mary, is now commonly sung between each Station of the Cross. This prayer, in which we ask Our Lady to help us experience the same sorrow and love with which she participated in her Son's Passion, has been set to music by many great composers. This episode explores the most famous and influential setting of Stabat Mater, completed by the 26-year-old Giovanni Battista Pergolesi (1710-1736) as he was dying of tuberculosis. An interview with leading Pergolesi scholar Francesco Cotticelli is combined with excerpts from the piece as recorded by La Nuova Musica (used with permission). Contents [2:11] The Stabat Mater text in the context of liturgy and Marian devotion [6:30] Pergolesi's bio and career [9:30] Aria from L'Olimpiade (used with permission from Lyubov Petrova) [17:37] Deathbed composition of the Stabat Mater [18:52] Pergolesi's place and innovations in sacred music of the time [23:07] First movement, Stabat Mater dolorosa [35:04] Second movement, Cuius animan gementem [40:32] Pergolesi's approach to text-setting: alternating between contemplation and action [43:20] Sixth movement, Vidit suum dulcem natum [50:35] Seventh movement, Eia, Mater, fons amoris [56:45] Musical characteristics of the baroque and galant styles [58:27] Ninth movement, Sancta mater, istud agas [1:11:44] Popular settings of the Stabat Mater before Pergolesi [1:12:49] Twelfth movement, Quando corpus morietur [1:17:20] The somber ending to the piece: hope amidst sorrow [1:20:30] Contemporary and later criticism of the piece for being too theatrical [1:23:11] Other interesting settings of the Stabat Mater Links Recording by La Nuova Musica (featured in this episode) http://www.harmoniamundi.com/#!/albums/2239 Also recommended: Recording by Concerto Italiano https://www.amazon.com/Pergolesi-Scarlatti-Stabat-Mater-Alessandrini/dp/B00CMSP1HU/ Website devoted to settings of the Stabat Mater https://www.stabatmater.info/ The text https://www.stabatmater.info/english-translation/ Lyubov Petrova sings Aristea's aria from Pergolesi's opera L'Olimpiade https://www.youtube.com/watch?v=H_SsVAXMMqo La Nuova Musica http://lanuovamusica.co.uk/ Lyubov Petrova https://imgartists.com/roster/29757/ This podcast is a production of CatholicCulture.org. If you like the show, please consider supporting us! http://catholicculture.org/donate/audio

Aristea Brady is an Emmy award winning anchor in Denver, CO, she is a Colorado native who was born and raised in Englewood. Prior to becoming Fox 31 News anchor, Aristea has been an anchor/reporter in Minneapolis, Salt Lake City and Lexington. Aristea is a graduate of Northwestern University’s Medill School of Journalism, where she doubled majored in broadcast journalism and legal studies. Sheryl and Aristea talk about the media world, including the impact social media and "fake news" proclaims have had on the industry.

Hello geeks, This week, we have a shorter ramble show. We chat painting, Pulp City and Aristea among other things. We also talk about Aelania the dragons charmer by Aradia Miniatures, and the Battle for Earth book and the Resistance Starter Fleet by TTCombat. So sit back, relax, grab a paintbrush and enjoy the show! Links[Aradia Miniatures] Aelania: dragons charmer[TTCombat] Battle for Earth[TTCombat] Resistance Starter Fleet Network We're part of the United Geeks Network. Check out their other great shows! Music Intro music is Aggressor by Free Stock Music.Breaks and outro music by La Drave. - The Geeks

Heat from the body can soften it making it more pliable and chewy. Chewy is a key word around its etymology. It’s a tree sap that is dried in the sun from only one place, the Greek island of Chios. It’s all about mastic, or mastiha in Greek or by it’s poetic name Tears of Chios. I’ll look at its history, rarity, value and its many uses. There's art by Émile Bayard, Elisabetta Duminuco and Clémentine Bal. Our guest Aristea Zougri of Althea Massage Therapy and Yoga has a myriad of skills and talents as a massage therapist, yoga practitioner with her own line of body oils. We chat about her career, holistic treatments, lots about the food of her native Greece and some of her mastiha memories.

Tassos Morfis is a talented Greek journalist and one of the founders of AthensLive, a non-profit newsroom based in Athens. He analyzes the media involvement in the latest refugee crisis in Greece and the public debate around it. Tassos tells Aristea the way Greece was used as a 'scapegoat' during the refugee crisis and how national and European media outlets were broadcasting the news. Among all those voices, someone could distinguish a far-right and terrorising rhetoric that reinforces or perpetuates ingrained biases and stereotypes. On the other hand, there were also sceptical and progressive narratives who gave another perspective on the 'established' dissemination plan of news full of racism and hate speech. The European Commission against Racism and Intolerance (ECRI), has developed specific recommendations about situations where minority groups, such as refugees and migrants, may be hindered in their access to equal rights because of discriminatory attitudes against them. As ECRI defines: "Hate speech […] entails the use of one or more particular forms of expression – namely, the advocacy, promotion or incitement of the denigration, hatred or vilification of a person or group of persons, as well as any harassment, insult, negative stereotyping, stigmatization or threat of such person or persons and any justification of all these forms of expression – that is based on a non-exhaustive list of personal characteristics or status that includes race, colour, language, religion or belief, nationality or national or ethnic origin, as well as descent, age, disability, sex, gender, gender identity and sexual orientation."

Nikos Paleologos, photo reporter with SOOC agency, explains how the media has been covering the big refugee influx and the way hate speech has re-entered the mainstream of Greek society. Nikos was there when boats full of people were arriving in Greek islands. He explains to Sotiris & Aristea the way the European and national media reacted and handled the situation. It has started as a shock for everyone. No one experienced something like that before. It was a new normality that the whole society had to cope with. News outlets as facilitators of public debate are widely considered as a strategic tool for managing the increasing diversity in society. When covering the arrivals of asylum seekers in Europe throughout 2015-2016 however, the media has played a central role in framing these events as a 'crisis'. This perspective contributed to negative and sometimes hostile attitudes amongst the public towards the newcomers.

Director of the Asylum Service in Greece, Dr. Markos Karavias, explains the procedure of becoming recognised as a refugee in Europe and why it takes so long. There is a story in Europe that the refugee crisis is over and that the numbers of arrivals are going down. That doesn't apply to countries like Greece or Cyprus. On our first episode, Markos Karavias tells Aristea about the growing number of asylum applications in Greece, the lack of competent interpreters, and what an asylum seeker should do in order to become or at least try to become documented. As of December 2018, almost 200,000 asylum applications have been lodged in Greece. According to data shared by the Asylum Service, in 2015, there were 13,187 applications submitted - a 39,8% increase from 2014 (9,431 applications). The EU-Turkey statement, signed one year later, on March 18, 2016, didn't really stop asylum seekers from risking their lives in the Aegean, and the numbers went up by 287,1% with 51,053 applications in total. The statistics for 2017 and 2018 show that Greece has turned from merely a country of transit into a country of destination for asylum seekers fleeing war in Middle East, with 58,642 and 61,760 applications submitted per year respectively.

On this episode, the gang gets together and takes a in depth look at the three current expansions of Aristea!. We also talk about the up coming Adpeticon 2019 events and what our plans our. Eric will be attending an … Continue reading →

For this final episode in the series I spoke to Aristea Fotopolou about her work on gender, data and self-tracking. She told me about her work on fertility and pregnancy apps and how they construct and embody discourses of gender, capitalism and neoliberalism. We question the extent to which we are encouraged to be "good citizens". In my view Aristea has some very interesting and useful ways of conceptualising the ways in which we engage with health and exercise tracking such as "biopedagogy" and focusing on the "micropractices" of using technology. Aristea tells me about her experience of conducting an autoethnography of her use of self-tracking and how her identity as a researcher and a research participant blurred. In the discussion Aristea connects the discussion of self-tracking to her other work on feminist activism and digital networks through suggesting that tracking is a form of gendered labour.

Martin Dangov (BG) interviews Aristea Tomopoulou (GREEK) The post Aristea Tomopoulou (Greek) #28timescinema #Venezia72 appeared first on Fred Education Channel » FRED Education Podcast. Aristea Tomopoulou (Greek) #28timescinema #Venezia72 was first posted on September 15, 2015 at 4:58 pm.©2015 "Fred Education Channel". Use of this feed is for personal non-commercial use only. If you are not reading this article in your feed reader, then the site is guilty of copyright infringement. Please contact me at radio@fred.fm